CL2023002895A1 - Anticuerpos anti-il-2r agonistas y métodos de uso - Google Patents
Anticuerpos anti-il-2r agonistas y métodos de usoInfo
- Publication number
- CL2023002895A1 CL2023002895A1 CL2023002895A CL2023002895A CL2023002895A1 CL 2023002895 A1 CL2023002895 A1 CL 2023002895A1 CL 2023002895 A CL2023002895 A CL 2023002895A CL 2023002895 A CL2023002895 A CL 2023002895A CL 2023002895 A1 CL2023002895 A1 CL 2023002895A1
- Authority
- CL
- Chile
- Prior art keywords
- antibodies
- methods
- agonist antibodies
- compositions
- il2rb
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170383P | 2021-04-02 | 2021-04-02 | |
| US202163239883P | 2021-09-01 | 2021-09-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023002895A1 true CL2023002895A1 (es) | 2024-02-02 |
Family
ID=81385128
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023002895A CL2023002895A1 (es) | 2021-04-02 | 2023-09-28 | Anticuerpos anti-il-2r agonistas y métodos de uso |
| CL2025001688A CL2025001688A1 (es) | 2021-04-02 | 2025-06-09 | Anticuerpo de cadena pesada anti-il2rb/il2rg; composición farmacéutica; y su uso. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2025001688A CL2025001688A1 (es) | 2021-04-02 | 2025-06-09 | Anticuerpo de cadena pesada anti-il2rb/il2rg; composición farmacéutica; y su uso. |
Country Status (18)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109862784A (zh) | 2016-08-24 | 2019-06-07 | 特尼奥生物股份有限公司 | 产生经修饰的仅有重链的抗体的转基因非人动物 |
| EP3559035A1 (en) | 2016-12-21 | 2019-10-30 | TeneoBio, Inc. | Anti-bcma heavy chain-only antibodies |
| EA202091557A1 (ru) | 2017-12-22 | 2020-11-18 | Тенеобио, Инк. | Антитела, содержащие только тяжелые цепи, которые связываются с cd22 |
| CA3133654A1 (en) | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| TW202304994A (zh) * | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗il-2r抗體及使用方法 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| TW202602940A (zh) | 2024-04-09 | 2026-01-16 | 美商安進公司 | 激動性抗il-2rbg重鏈抗體 |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2026033139A1 (en) | 2024-08-09 | 2026-02-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| JP3255699B2 (ja) | 1992-04-23 | 2002-02-12 | 味の素株式会社 | ヒトIL−2レセプターγ鎖分子 |
| WO1996021732A1 (en) | 1995-01-09 | 1996-07-18 | Boehringer Ingelheim International Gmbh | Il-2r-associated polypeptide and dna molecules coding therefor |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| AU2937597A (en) | 1996-05-10 | 1997-12-05 | Biogen, Inc. | Common gamma chain blocking agents |
| US6103879A (en) | 1996-06-21 | 2000-08-15 | Axys Pharmaceuticals, Inc. | Bivalent molecules that form an activating complex with an erythropoietin receptor |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| JP2006505546A (ja) | 2002-10-10 | 2006-02-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 二重特異性抗ErbB抗体および腫瘍治療でのその使用 |
| MXPA05004677A (es) | 2002-10-31 | 2005-11-17 | Genentech Inc | Metodos y composiciones para aumentar la produccion de anticuerpos. |
| WO2004065417A2 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| EP1776383B1 (en) | 2004-07-22 | 2014-08-20 | Erasmus University Medical Center Rotterdam | Binding molecules |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| CN102421801B (zh) | 2009-03-10 | 2016-03-16 | 比奥根Ma公司 | 抗-bcma抗体 |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| EP2560994B1 (en) | 2010-04-08 | 2016-10-12 | JN Biosciences LLC | Antibodies to cd122 |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| RU2693078C2 (ru) | 2012-12-03 | 2019-07-01 | Новиммун С.А. | Анти-cd47 антитела и способы их применения |
| US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| US10239951B2 (en) | 2013-05-08 | 2019-03-26 | Zymeworks Inc. | Bispecific HER2 and HER3 antigen binding constructs |
| PT3328894T (pt) * | 2015-08-06 | 2019-02-13 | Agency Science Tech & Res | Anticorpos de cadeia comum gama/il2rbeta |
| IL299221A (en) | 2016-06-21 | 2023-02-01 | Teneobio Inc | Cd3 binding antibodies |
| CN109862784A (zh) | 2016-08-24 | 2019-06-07 | 特尼奥生物股份有限公司 | 产生经修饰的仅有重链的抗体的转基因非人动物 |
| CR20220578A (es) | 2016-09-14 | 2023-01-17 | Teneobio Inc | Anticuerpos de unión a cd3 |
| CN111954680B (zh) | 2017-11-10 | 2024-03-15 | 新加坡科技研究局 | IL2Rβ/共同γ链抗体 |
| WO2020094836A1 (en) * | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
| WO2020094834A1 (en) * | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
| CN113474370B (zh) | 2019-02-01 | 2025-04-01 | 瑞泽恩制药公司 | 抗IL2受体γ抗原结合蛋白 |
| TW202304994A (zh) * | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗il-2r抗體及使用方法 |
-
2022
- 2022-03-31 TW TW111112596A patent/TW202304994A/zh unknown
- 2022-04-01 JP JP2023559727A patent/JP2024512982A/ja active Pending
- 2022-04-01 EP EP22718473.6A patent/EP4314067A1/en active Pending
- 2022-04-01 IL IL305944A patent/IL305944A/en unknown
- 2022-04-01 PH PH1/2023/552763A patent/PH12023552763A1/en unknown
- 2022-04-01 WO PCT/US2022/023058 patent/WO2022212848A1/en not_active Ceased
- 2022-04-01 MX MX2023011624A patent/MX2023011624A/es unknown
- 2022-04-01 BR BR112023020219A patent/BR112023020219A2/pt unknown
- 2022-04-01 PE PE2023002728A patent/PE20240913A1/es unknown
- 2022-04-01 KR KR1020237035936A patent/KR20230165263A/ko active Pending
- 2022-04-01 UY UY0001039715A patent/UY39715A/es unknown
- 2022-04-01 CR CR20230507A patent/CR20230507A/es unknown
- 2022-04-01 CA CA3214587A patent/CA3214587A1/en active Pending
- 2022-04-01 AU AU2022252398A patent/AU2022252398A1/en active Pending
-
2023
- 2023-02-03 US US18/164,442 patent/US11884735B2/en active Active
- 2023-08-29 US US18/457,553 patent/US12590163B2/en active Active
- 2023-09-26 JO JOJO/P/2023/0234A patent/JOP20230234A1/ar unknown
- 2023-09-28 CL CL2023002895A patent/CL2023002895A1/es unknown
- 2023-10-23 CO CONC2023/0014054A patent/CO2023014054A2/es unknown
-
2025
- 2025-06-09 CL CL2025001688A patent/CL2025001688A1/es unknown
-
2026
- 2026-03-05 US US19/557,943 patent/US20260176366A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CR20230507A (es) | 2023-12-12 |
| MX2023011624A (es) | 2023-10-11 |
| CA3214587A1 (en) | 2022-10-06 |
| US20240018250A1 (en) | 2024-01-18 |
| KR20230165263A (ko) | 2023-12-05 |
| JOP20230234A1 (ar) | 2023-09-26 |
| US12590163B2 (en) | 2026-03-31 |
| US11884735B2 (en) | 2024-01-30 |
| CL2025001688A1 (es) | 2025-08-18 |
| IL305944A (en) | 2023-11-01 |
| US20230242653A1 (en) | 2023-08-03 |
| TW202304994A (zh) | 2023-02-01 |
| BR112023020219A2 (pt) | 2024-02-06 |
| CO2023014054A2 (es) | 2023-11-10 |
| AU2022252398A9 (en) | 2024-01-11 |
| WO2022212848A1 (en) | 2022-10-06 |
| US20260176366A1 (en) | 2026-06-25 |
| AU2022252398A1 (en) | 2023-09-21 |
| UY39715A (es) | 2022-10-31 |
| PH12023552763A1 (en) | 2024-04-15 |
| JP2024512982A (ja) | 2024-03-21 |
| PE20240913A1 (es) | 2024-04-30 |
| EP4314067A1 (en) | 2024-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023014054A2 (es) | Anticuerpos anti-il-2r agonistas y métodos de uso | |
| MX2022002740A (es) | Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes. | |
| SA520411204B1 (ar) | مترافقات سيتوكين لعلاج الأمراض التكاثرية والمعدية | |
| ECSP19078502A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
| CL2021003196A1 (es) | Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 (divisional de solicitud n° 201902850) | |
| MX2021012205A (es) | Anticuerpos de cadena pesada que se unen al psma. | |
| DOP2024000207A (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| MX2021009259A (es) | Conjugados de il-2 y metodos de uso del mismo. | |
| MX2023009874A (es) | Anticuerpos anti-psma y estructuras car-t. | |
| JOP20220020B1 (ar) | مثبطات kars تعتمد على akr1c3 ثلاثية الحلقة | |
| CL2021001395A1 (es) | Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades. | |
| MX2021005822A (es) | Derivados de bis-octahidrofenantreno carboxamida y conjugados de proteinas de los mismos para usarse como agonistas de lxr. | |
| CL2024000459A1 (es) | Tubulisinas y conjugados de proteína-tubulisina. | |
| UY39522A (es) | Anticuerpos de cadena pesada que se unen al receptor alfa de folato | |
| MX2021015154A (es) | Composicion farmaceutica parenteral de agonista dual de glp1/2. | |
| CO2023013500A2 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
| CO2023013543A2 (es) | Anticuerpos anti-cd20 y estructuras car-t | |
| UY38937A (es) | AGENTES DE iARN PARA INHIBIR LA EXPRESIÓN DEL ENaC BETA, COMPOSICIONES DE ESTOS Y MÉTODOS DE USO | |
| MX2018016051A (es) | Composiciones y métodos para diagnosticar tipos de cáncer de pulmón usando perfiles de expresión génica. | |
| MX2024012582A (es) | Composiciones farmaceuticas de proteinas terapeuticas y metodos de uso | |
| MX2021014729A (es) | Metodos y composiciones para tratar enfermedades autoinmunitarias. | |
| CO2020012484A2 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") | |
| CO2022015105A2 (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| DOP2025000322A (es) | Anticuerpos de nectina-4 y conjugados anticuerpo-fármaco | |
| EA202190660A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение |